

Resource Summary Report

Generated by [dkNET](#) on Sep 22, 2026

Recombinant Anti-FOXP3 antibody [EPR22102-37]

RRID:AB_2860568

Type: Antibody

Proper Citation

Abcam Cat# ab215206, RRID:AB_2860568

Antibody Information

URL: http://antibodyregistry.org/AB_2860568

Proper Citation: Abcam Cat# ab215206, RRID:AB_2860568

Target Antigen: FOXP3

Host Organism: rabbit

Clonality: recombinant

Comments: Applications: WB, IP, Flow Cyt, IHC-P

Antibody Name: Recombinant Anti-FOXP3 antibody [EPR22102-37]

Description: This recombinant targets FOXP3

Target Organism: rat, mouse, human

Clone ID: EPR22102-37

Antibody ID: AB_2860568

Vendor: Abcam

Catalog Number: ab215206

Record Creation Time: 20231110T032037+0000

Record Last Update: 20260829T143703+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-FOXP3 antibody [EPR22102-37].

No alerts have been found for Recombinant Anti-FOXP3 antibody [EPR22102-37].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Wang Y, et al. (2026) AARS1 promotes tumor progression and immune evasion via ATF6 lactylation-mediated tryptophan metabolism in hepatocellular carcinoma. *Cell metabolism*, 38(8), 1702.

Luo Y, et al. (2026) CCL5 deficiency aggravates acute DSS-induced colitis by restricting IL-33-induced formation of Tregs in intestinal tract. *Clinical science (London, England : 1979)*, 140(1).

Nakanishi N, et al. (2026) VEGF-C-mediated cardiac lymphangiogenesis promotes inflammation resolution in autoimmune acute myocarditis in mice. *Cardiovascular research*, 122(6), 707.

Gu J, et al. (2025) Tumor-produced ammonia is metabolized by regulatory T cells to further impede anti-tumor immunity. *Cell*.

Han S, et al. (2025) Inhibition of KAT6A enhances immunotherapy efficacy in colorectal cancer by activating interferon response. *Cancer letters*, 631, 217946.

Nie RC, et al. (2025) Safety and efficacy of perioperative dual PD-1 and HER2 blockade in HER2-positive gastric cancer. *Cell reports. Medicine*, 6(6), 102190.

Iturri L, et al. (2025) Evaluation of Proton Minibeam Radiotherapy on Antitumor Immune Responses in a Rat Model of Glioblastoma. *Cancer immunology research*, 13(11), 1854.

Zhong S, et al. (2025) Genomic landscape and immunological profile of glioblastoma in East Asian patients. *Cell reports. Medicine*, 6(8), 102217.

Yao Y, et al. (2025) Short-chain fatty acids regulate T cell heterogeneity to alleviate recurrent spontaneous abortion. *British journal of pharmacology*.

Cao C, et al. (2024) CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8+ T cells via JAK2/STAT3 pathway. *Cell genomics*, 4(10), 100659.

Ding R, et al. (2024) Lactate modulates RNA splicing to promote CTLA-4 expression in tumor-infiltrating regulatory T cells. *Immunity*, 57(3), 528.

Luo Y, et al. (2024) Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. *Cell*, 187(18), 4905.

Ning J, et al. (2024) Macrophage-coated tumor cluster aggravates hepatoma invasion and immunotherapy resistance via generating local immune deprivation. *Cell reports. Medicine*, 5(5), 101505.

Xiao X, et al. (2023) ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy. *Nature communications*, 14(1), 2859.

Bertho A, et al. (2023) Evaluation of the Role of the Immune System Response After Minibeam Radiation Therapy. *International journal of radiation oncology, biology, physics*, 115(2), 426.

Tang R, et al. (2023) Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response. *Cell reports. Medicine*, 4(10), 101234.

Liu L, et al. (2023) Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity. *Cell reports. Medicine*, 4(10), 101206.

Gu J, et al. (2022) Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF- β signaling in regulatory T cells. *Cell reports*, 39(12), 110986.

Wen J, et al. (2022) Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma. *EBioMedicine*, 86, 104371.

Zheng KF, et al. (2021) PD-L1 expression and immune cells infiltration in primary tracheobronchial neoplasm. *Translational lung cancer research*, 10(12), 4617.